Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration-Reference-Cited by-同舟云学术

Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration

Published:2020-02-01 Issue:2 Volume:180 Page:301
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Heyward James¹,Olson Lily¹,Sharfstein Joshua M.¹²,Stuart Elizabeth A.³,Lurie Peter⁴,Alexander G. Caleb¹⁵⁶

Affiliation:

1. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

2. Office of Public Health Practice and Training, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

3. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

4. Center for Science in the Public Interest, Washington, DC

5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

6. Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2757791/jamainternal_heyward_2019_rv_190004.pdf

Reference28 articles.

1. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.;Cicero;Pharmacoepidemiol Drug Saf,2007

2. Emergency department visits among recipients of chronic opioid therapy.;Braden;Arch Intern Med,2010

3. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.;Bucher Bartelson;Pharmacoepidemiol Drug Saf,2017

4. ER/LA opioid analgesics REMS: overview of ongoing assessments of its progress and its impact on health outcomes.;Cepeda;Pain Med,2017

5. SCOPE of pain: an evaluation of an opioid Risk Evaluation and Mitigation Strategy continuing education program.;Alford;Pain Med,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Warning Labels as a Public Health Intervention: Effects and Challenges for Tobacco, Cannabis, and Opioid Medications;Annual Review of Public Health;2024-05-20

2. Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review;American Heart Journal Plus: Cardiology Research and Practice;2024-02

3. Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use;PLOS ONE;2023-07-06

4. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine–Topiramate to Prevent Exposure During Pregnancy;Annals of Internal Medicine;2023-04

5. Risk Management and Communication: Building Trust and Credibility With the Public;Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology;2023